Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.

Cancer biology & therapy - 2 Dec 2017

Head R J, Fay M F, Cosgrove L, Y C Fung K, Rundle-Thiele D, Martin J H

Abstract excerpt

Glioblastoma is a lethal form of brain tumour usually treated by surgical resection followed by radiotherapy and an alkylating chemotherapeutic agent. Key to the success of this multimodal approach is maintaining apoptotic sensitivity of tumour cells to the alkylating agent. This initial treatment likely establishes conditions contributing to development of drug resistance as alkylating agents form the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to DNA Adducts

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to Glioblastoma

Share to Guanine

Share to Neoplasm Recurrence, Local

Source

Open in PubMed Open full text

Identifiers

PMID: 29020502
DOI: 10.1080/15384047.2017.1385680
PMCID: PMC5718815

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.PMID 29020502Read ↗

Mechanisms of Chemoresistance to Alkylating Agents in Malignant GliomaSemantic proximity Read ↗

Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in GlioblastomaSemantic proximity Read ↗

DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targetsSemantic proximity Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Temozolomide: Mechanisms of Action, Repair and ResistanceSemantic proximity Read ↗

DNA repair mechanisms and their clinical impact in glioblastomaSemantic proximity Read ↗

Understanding and Targeting Alkylator Resistance in GlioblastomaSemantic proximity Read ↗

DNA Damage Response in GlioblastomaSemantic proximity Read ↗

Temozolomide and Other Alkylating Agents in Glioblastoma TherapySemantic proximity Read ↗

The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and ResistanceSemantic proximity Read ↗

Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomideSemantic proximity Read ↗

Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.